Gam-COVID-Vac Drug Asset Due Diligence Report 2026

This Gam-COVID-Vac Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Gam-COVID-Vac can convert its Recombinant vector vaccine, Prophylactic vaccine profile and SARS-CoV-2 S protein biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Gam-COVID-Vac (query alias: Gam-COVID-Vac)
Modality / target	Recombinant vector vaccine, Prophylactic vaccine; SARS-CoV-2 S protein; SARS-CoV-2 S protein inhibitors
Highest global status	Approved
Originator	Gamaleya Research Institute Of Epidemiology And Microbiology, Health Ministry Of The Russian Federation
Active developers	Gamaleya Research Institute Of Epidemiology And Microbiology, Health Ministry Of The Russian Federation, Gamaleya Research Institute Of Epidemiology And Microbiology

The MCP disease footprint includes COVID-19. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTRI/2022/06/043447	Phase 4	Not Yet Recruiting	1542	Not disclosed
NCT06068556	Phase 3	Unknown status	50	Occurrence of adverse events (AE)
NCT06068569	Phase 3	Not yet recruiting	50	Occurrence of adverse events (AE)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case-control study.

Not Applicable; n=23996; evaluation: Positive. Reported fields: VE against any lung injury = 2 % (95%CI, -27 to 24)

CML-127 Results of a Vaccination Against COVID-19 by a Vector Based Vaccine Sputnik V in Patients With Chronic Myeloid Leukemia

Not Applicable; n=not disclosed; evaluation: Positive. Reported fields: Antibodies = 93 %

Safety and immunogenicity of Sputnik-V, AstraZeneca and Sinopharm vaccines against SARS-CoV-2 in people living with HIV

Not Applicable; n=867; evaluation: not stated. Reported fields: AEFIs = 60.4 % ; AEFIs = 29.5 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Gam-COVID-Vac addresses COVID-19. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Recombinant vector vaccine, Prophylactic vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-11-12	西藏诺迪康药业与俄罗斯LIMITED LIABILITY COMPANY 'HUMAN VACCINE'公司就Sputnik-V vaccine（新冠肺炎腺病毒疫苗）开展合作	Phase 2	US$32.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO